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ARTICLE OPEN
Relation between NOD2 genotype and changes in innate
signaling in Crohn’s disease on mRNA and miRNA levels
Yun Chen1, Mohammad Salem2, Mette Boyd1, Jette Bornholdt1, Yuan Li2, Mehmet Coskun1,2, Jakob Benedict Seidelin2,
Albin Sandelin 1 and Ole Haagen Nielsen2
Crohn’s disease is associated with an altered innate immune response of pathogenic importance. This altered response can be
associated to loss-of-function polymorphisms in the NOD2 (nucleotide-binding oligomerization domain-containing protein 2) gene,
but also changes in transcriptional and post-transcriptional regulatory layers, including microRNA activity. Here, we characterized
the link between NOD2 genotype and inﬂammatory-mediated changes in innate signaling by studying transcriptional and post-
transcriptional activity in response to NOD2-agonist muramyl dipeptide in monocytes from healthy controls, and Crohn’s disease
patients with and without NOD2 loss-of-function polymorphisms. We measured the expression of genes and microRNAs in
monocytes from these subjects after stimulation with muramyl dipeptide. Gene expression proﬁles mainly distinguished the actual
muramyl dipeptide response, but not the genotype. A hyper-responsive phenotype was found in Crohn’s disease patients without
NOD2 mutations, characterized by upregulated cytokine receptors and general downregulation of microRNA expression.
Conversely, microRNA expression could identify genotype-speciﬁc differences between subject groups but exhibited little change
upon muramyl dipeptide treatment. Only two microRNAs showed muramyl dipeptide-induced response, including miR-155, which
was found to regulate multiple genes and whose host gene was one of the highest muramyl dipeptide responders. miR-155 was
upregulated in Crohn’s disease patients with NOD2 mutations following lipopolysaccharide and Escherichia coli treatment, but the
upregulation was substantially reduced upon muramyl dipeptide treatment. While Crohn’s disease patients with NOD2 mutations
on average showed a reduced muramyl dipeptide response, the cohort exhibited large individual variance: a small subset had
inﬂammatory responses almost comparable to wild-type patients on both gene and miR-155 regulatory levels.
npj Genomic Medicine  (2017) 2:3 ; doi:10.1038/s41525-016-0001-4
INTRODUCTION
Crohn’s disease (CD)1 constitutes together with ulcerative colitis
(UC)2 the two most prevailing disorders under the umbrella term
inﬂammatory bowel disease (IBD).3 CD can affect any part of the
gastrointestinal tract but most often the ileocecal region. General
clinical manifestations of intermitting bowel inﬂammation are
associated with abdominal pain, fever, prolonged diarrhea, and/or
weight loss.4 In CD, genetic variations and environmental factors
such as altered microbiota interact to produce the inﬂammatory
background of the disease.1, 5 Along with changes in the adoptive
immune system, an impaired innate immunity is believed to play a
crucial role in the immunopathogenesis of CD.
Epidemiologic and linkage studies suggest that genetic factors
play a clinical role in determining CD susceptibility.6, 7 One of the
key genes identiﬁed through these studies is NOD2 (nucleotide-
binding oligomerization domain-containing protein 2),8, 9 encod-
ing a cytosolic pathogen recognition receptor that speciﬁcally
binds to muramyl dipeptide (MDP), the smallest bioactive
component of peptidoglycans present in most bacteria.10 Activa-
tion of NOD2 leads to induction of key immune signaling
pathways involved in CD pathogenesis, including the upregulation
of various pro-inﬂammatory cytokines.11 In addition, continuous
MDP stimulation inhibits the development of experimental colitis
in animal models,12 suggesting that normally functioning NOD2
signaling pathways might be directly involved in protecting and
maintaining the intestinal homeostasis. Furthermore, innate
signaling is altered even in NOD2 wild-type (WT) CD patients,13
implying post-transcriptional modiﬁcations of NOD2 signaling
pathways could be involved in re-establishment of normal innate
responses, and this mechanism could be a future therapeutic
target aiming at restoring microbial responses in CD. In this
context, recent studies have linked NOD2 to crucial post-
transcriptional changes, including regulation by microRNAs
(miRNAs) in different intestinal epithelial cell lines.14–16 miRNAs
are short structured RNAs that play important roles in the
regulation of gene transcription and translation in development
and disease progression, including CD.17, 18 One of the most well-
known miRNA regulators associated with inﬂammation and innate
immunity is miR-155.19–22 Previous studies have shown an
elevated level of miR-155 in colonic mucosa of CD and UC,23, 24
and depletion of miR-155 protects from experimental colitis in
mice.25 Different pathogenic stimuli induce miR-155 in vitro,
including viral infection20, 26, 27 and lipopolysaccharide (LPS).28
However, the role of miR-155 in immune cells in the context of CD
and NOD2 polymorphisms is not well established.
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There are three major single-nucleotide polymorphisms (SNPs)
of the NOD2 gene (SNP8, SNP12, and SNP13) that are strongly
associated to CD and cause a loss-of-function phenotype with a
reduced response to MDP.11 SNP8 and SNP12 are missense
mutations, whereas SNP13 is a frameshift mutation with the most
drastic loss-of-function phenotype.29 The link between SNPs in
NOD2 and CD-associated inﬂammatory responses might have
implications for the disease not only because an innate immune
dysfunction is important for the pathogenesis of CD, but also since
normalization of innate signaling alleviates colitis.12, 30 However,
controversies exist on how alterations in NOD2 signaling can lead
to an increased susceptibility to inﬂammation, and what the role
of post-transcriptional regulation in patients with/without disease-
associated NOD2 variants are for the resulting pathogenic innate
immune response.11 Therefore, transcriptional proﬁles of NOD2
mutant cells responding to MDP or bacterial stimulation have
been analyzed using coverage-limited microarrays and focused
either on mRNAs or miRNAs. The miRNA–mRNA regulation studies
were either a single-target study31 or done in non-primary cells or
immune cells derived from non-CD subjects.15, 32 Thus, it is
important to investigate the interactions between miRNAs and
genes genome-wide in patient-derived cells, and study how this is
affected in innate immune response as function of different NOD2
genotypes. To do this, it is necessary to investigate both RNA
species from the same cells upon inﬂammation induction in cells
with and without NOD2 loss-of-function SNPs.
To this end, in this study we measured the expression of genes
and miRNAs in human blood monocytes before and after MDP
stimulation using genome-wide RNA and small RNA sequencing in
an exploratory cohort consisting of healthy control subjects and
CD patients with/without NOD2 loss-of-function SNPs (N = 7 in
total), and subsequently validated our major ﬁndings in larger
patient groups (N = 29, in total) as well as all identiﬁed miRNA-
gene interaction candidates in the THP-1 cell line (N = 8). Our data
suggest that gene expression effectively identiﬁes pathological
MDP/NOD2-associated immune gene responses in blood mono-
cytes from subjects without NOD2 loss-of-function mutations. A
pre-inﬂammatory, hyper-responsive phenotype was found in CD
patients without NOD2 loss-of-function SNPs. Conversely, the
miRNA regulatory layer was surprisingly static before and after
MDP stimulation, but could predict subject and genotype groups
regardless of MDP treatment. Only two miRNAs, miR-190A and
miR-155, responded to MDP. CD patients with NOD2 loss-of-
function SNPs were, as expected, on average less responsive to
MDP compared to other subjects at both gene and miR-155 levels,
but these patients displayed a surprisingly large variance in their
responses ranging from a total loss to a nearly intact inﬂammatory
response. Although NOD2 loss-of-function SNP patients displayed
reduced miR-155 induction after MDP treatment, miR-155 induc-
tion was unchanged when treating with LPS or intact bacteria
treatment, suggesting that NOD2 mutations only affect NOD2-
pathway-elicited response and not other inﬂammatory pathways.
RESULTS
Differential expression proﬁles between CDWT, CDNOD2, and
control subjects
We ﬁrst analyzed the miRNA and gene expression signatures
between the three subject groups: CDWT, CDNOD2, and controls using
small RNA-Seq and RNA-Seq as deﬁned in the “Methods” section
before MDP treatment (green arrows, Fig. 1 and top of Fig. 2a,b) and
after MDP treatment (yellow arrows, Fig. 1 and top of Fig. 2c,d).
Intriguingly, the miRNA expression signature could separate the
three subject groups (controls, CDNOD2, and CDWT) both before
and after MDP treatment. In both states, control subjects and
CDNOD2 patients were more similar to each other than CDWT
patients, where many miRNAs were more lowly expressed
compared to the other two groups (Fig. 2a,c). Thus, the overall
miRNA population was downregulated in CDWT patients, suggest-
ing an overall lower impact of miRNA-mediated gene repression in
this group.
In contrast, the differences of gene expression could not
distinguish subject groups as clearly as the miRNA expression,
because the differences between subject groups were much
smaller than that observed by miRNA expression (see dendrogram
in Fig. 2b,d, and Supplementary Fig. 1a, b).
We next analyzed the differentially expressed miRNAs and
genes identiﬁed in these two analyses. Nearly half of miRNAs
(42%, 5/12) that were differentially expressed between subject
groups before MDP treatment were also differentially expressed
between subject groups after MDP treatment (Fig. 2e, Venn
diagram in the left panel). The expression levels of these shared
miRNAs were highly consistent before and after MDP treatment
(Supplementary Fig. 2a); thus, the overall regulatory layer of
miRNAs seemed to be independent of MDP signaling between
groups, and could at the same time separate the subject groups.
Indeed, the ﬁve miRNAs that were differentially expressed
between groups regardless of treatment could alone distinguish
subject groups (but not MDP treatment) efﬁciently (Fig. 2e,
dendrogram in the right panel).
In contrast, only around 10% (13/108, Fig. 2f, also see
Supplementary Fig. 1c) of genes that were signiﬁcantly different
between subject groups before MDP treatment were also
signiﬁcantly different between patient groups after MDP treat-
ment. These shared genes could not separate the subject groups
(Fig. 2f, dendrogram in the left panel). Consistently, these genes
displayed a wide expression difference between subjects before
and after MDP (Supplementary Fig. 2b). Genes that were
differentially expressed between subject groups before MDP
stimulation showed an enrichment of gene ontology (GO) terms
relating to defense response, inﬂammatory response, response to
wounding, and response to virus (Fig. 3a and Supplementary Fig.
3a). In contrast, genes differentially expressed between patient
genotype groups after MDP treatment were enriched in chemo-
kine and cytokine-related functions (Fig. 3b and Supplementary
Fig. 3b). Quantitative PCR (qPCR) analysis for two selected
chemokines, CXCL1 and CCL2, in a larger cohort conﬁrmed
upregulation after MDP treatment in healthy controls and CDWT,
but not in CDNOD2 patients (Fig. 3c,d; Supplementary Fig. 3c, d
show corresponding RNA-Seq data). This is consistent with the
established link between NOD2 and cytokine induction through
the NF-κB pathway.11
miRNA and gene expression response to MDP
In order to investigate cell response to MDP, we compared the
difference in miRNA and gene expression before vs. after MDP
treatment within each patient group (red arrows in Fig. 1b and top
of Fig. 4). Consistent with the analysis above, only two miRNAs
(miR-155 and miR-190A) were signiﬁcantly changed as a response
to MDP in any pairwise comparison. Because miR-155 was much
higher expressed than miR-190A (Fig. 4a, left panel), and was
previously established as a key inﬂammatory regulator,21, 22, 33 we
validated its expression change by qPCR in the larger validation
cohort. The results showed that miR-155 was signiﬁcantly
upregulated in controls and CDWT, but not in CDNOD2 after MDP
treatment (P≤ 0.05, paired two-sided t-test) (Fig. 4a, right panel;
Supplementary Fig. 4a shows corresponding small RNA-Seq data).
Notably, there was no difference in miR-155 upregulation between
CDWT and CDNOD2 patients when cells were treated with either LPS
or intact intestinal Escherichia coli bacteria (Fig. 4b). Thus, miR-155
could be upregulated by multiple inﬂammatory stimuli but only
the MDP-triggered upregulation was dependent on the NOD2
genotype. This makes sense, as NOD2 is a speciﬁc sensor for MDP,
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while LPS and E. coli activate other NOD2-independent inﬂamma-
tory pathways.
Conversely, the gene expression proﬁles were drastically
different after MDP treatment (Fig. 4c, left panel and Supplemen-
tary Fig. 4b) and could distinguish treated vs. non-treated samples
with the exception of one CDNOD2 sample (see black arrows in
Fig. 4c and Supplementary Fig. 4b). qPCR analysis in the larger
validation cohort conﬁrmed the changes in selected differential
expressed genes (Fig. 4c, right panel and Supplementary Fig. 4c–f).
Notably, CDWT patients had more than six times the number of
upregulated genes than healthy controls (1095 vs. 181, Fig. 4d;
also see Supplementary Fig. 4g). Moreover, the large majority of
upregulated genes in healthy controls (86%, 156/181) were also
upregulated in CDWT patients. To test whether these 156 shared
upregulated genes had the same magnitude of MDP response, we
plotted the average gene expression fold change after MDP in the
healthy control group vs. corresponding fold change in the CDWT
group (Supplementary Fig. 4h). In general, genes with high
upregulation in the healthy control group had even higher
upregulation in CDWT patients. This was also true for the host gene
of miR-155, consistent with the higher upregulation of mature
miR-155 in CDWT (Fig. 4a), and indicating an important role for
miR-155 in MDP response in CD conditions.
Conversely, in the CDNOD2 patients, no genes were signiﬁcantly
upregulated or downregulated as a response to MDP (only ten
genes were induced using the alternative signiﬁcance calculation
method, Supplementary Fig. 4g).
Together, these observations indicated that only subjects with
WT NOD2 (healthy controls and CDWT patients) had substantial
MDP-induced responses and CDWT patients had a stronger and
wider MDP response. To investigate the responses only found in
CDWT patients further, we mapped the shared upregulated genes
between CDWT and control subjects and the genes only
upregulated in CDWT subjects onto cytokine-receptor KEGG
pathways.34 Strikingly, the receptors for upregulated cytokines
were primarily upregulated in CDWT patients but not in healthy
controls (Supplementary Fig. 5a, b), suggesting that the down-
stream inﬂammatory response in these pathways was blocked or
diminished in healthy controls even if the relevant cytokines were
present. These results strongly imply that CDWT patients had a
wider inﬂammatory response including substantial activation of
chemokine receptors and their downstream signaling pathways.
Thus, these patients could be characterized as a phenotype with
pre-inﬂammatory hyper-reactive innate response. An investigation
of MDP-dependent downregulated genes showed that although
the number of downregulated genes was smaller than upregu-
lated genes, the results were consistent to the pattern observed
above: on gene level, CDWT patients had a stronger and wider
MDP-mediated inﬂammatory response than healthy controls,
while CDNOD2 patients typically lost the majority of the inﬂamma-
tory response to MDP (Fig. 4e and Supplementary Fig. 4g, h).
While we observed no signiﬁcant gene changes upon MDP
stimulation in CDNOD2 patients, the MDP states of two CDNOD2
subjects could be distinguished using gene expression proﬁles
(see dendrogram in Fig. 4c, left panel). Thus, we reasoned that
subtle expression changes might exist, and that the type of NOD2
mutation might inﬂuence the degree of expression change. To
investigate this further, we focused on the genes found
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Fig. 1 Overview of cohorts and differential expression analyses. Monocytes were derived from three subject groups: healthy controls, CD
patients with WT NOD2 genotypes (CDWT), and CD patients with loss-of-function NOD2 genotypes (CDNOD2). Monocytes were analyzed by
RNA-Seq and small RNA-Seq (black body outlines, number of tested individuals is indicated), and selected genes and miRNAs were validated
by qPCR in a validation cohort (blue body outlines, number of tested individuals is indicated). We analyzed the difference between subject
groups, before and after MDP stimulation (green and yellow arrows, shown in Figs. 2,3), and the response to MDP stimulation within each group
(red arrows, shown in Fig. 4)
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upregulated and downregulated upon MDP treatment in CDWT
(1095 and 565 genes, respectively). For each CDNOD2 sample we
plotted the RNA-Seq gene expression fold change after MDP
treatment vs. the average gene expression fold change after MDP
in the CDWT group (Fig. 4f,g, and Supplementary Fig. 4g, right
panels). While this conﬁrmed the overall lower inﬂammatory
response in CDNOD2 samples vs. CDWT, it also showed clear
differences in inﬂammatory response across the individual CDNOD2
samples. This was consistent between upregulated and down-
regulated genes and was particularly clear for genes with high fold
changes. This indicated the loss of inﬂammatory responses in
CDNOD2 patients was not binary but a gradient across individuals.
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Fig. 2 miRNA and gene expression patterns between subject groups. a Heat map showing the expression pattern of differentially expressed
miRNAs between subject groups before MDP stimulation (green arrows in Fig. 1, also shown as schematics on top). Expression values are
broken into permilles and assigned to a color gradient ranging from red (high expression) to blue (low expression). Rows indicate individual
miRNAs, while columns show individual subjects. Rows and columns are ordered by hierarchical clustering using Euclidian distance, where the
top dendrogram indicate similarity between subjects. Subject groups and MDP treatment are indicated by color above the heat maps. Note
the clear separation between CDWT, CDNOD2, and controls. b As in a, but showing differentially expressed genes (by RNA-Seq) between subject
groups before MDP treatment. c As in a, but showing differentially expressed miRNAs between subject groups after MDP stimulation. Note
the clear separation between CDWT, CDNOD2, and controls. d As in a, but showing differentially expressed genes between subject groups after
MDP treatment. e Left: Venn diagram showing the overlap between differentially expressed miRNAs between subject groups before and after
MDP treatment. Right: expression-based clustering of the ﬁve shared miRNAs as in a, but only showing subjects, treatments, and the resulting
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To verify our observation in a larger cohort, we measured the
expression of seven validated MDP-responsive genes in CDWT
(three upregulated genes: CXCL1, CCL2, and IRAK2; four down-
regulated genes: MAPK3, MAVS, PALD1, and FLI1) in eight CDNOD2
and eleven CDWT samples before and after MDP treatment
by qPCR (Fig. 4h). From this analysis, the large variance in
inﬂammatory response was evident: some CDNOD2 patients
showed virtually no inﬂammatory response, while some had
inﬂammatory responses comparable to CDWT subjects. Overall, in
our set, CDNOD2 patients carrying SNP13 HOM had the lowest
responses to inﬂammation induced by MDP (Fig. 4f–h and
Supplementary Fig. 4g).
miRNA-gene associations in MDP response
The analyses above did not take miRNA-elicited regulation of gene
expression into account. To identify likely regulatory miRNA-gene
associations, we used experimentally veriﬁed miRNA targets from
mirTarBase 4.3,35 and required that the miRNA and gene pair in
question had anti-correlated expression patterns (e.g., upregula-
tion of miRNA and downregulation of gene, or vice versa) in any of
the previously made pairwise expression analyses (any arrow in
Fig. 1). When including all the differentially expressed miRNAs and
genes, only 16 putative miRNA-gene pairs centered on miR-155
were identiﬁed (Fig. 5a). To further consolidate the regulatory role
of miR-155, we transfected pre-miR-155 into human monocytic
THP-1 cells and measured the expression change of the 16
candidate target genes with qPCR (Fig. 5a). Of these, PALD1, FLI1,
PCYOX1, and BRI3BP were signiﬁcantly repressed upon miR-155
transfection (P≤ 0.05, two-sided t-test, Fig. 5b–e), while TYSND1,
TM6SF1, and SKI were borderline signiﬁcant (Fig. 5f–h, for details
see “Methods”). It is important to consider that this type of
experiment may include indirect effects; however, several of the
genes had additional external evidence in the form of gene
reporter assays (external evidence is summarized in Fig. 5i).
We found that this limited set of seven validated miR-155
targeting genes alone could distinguish MDP-treated cells from
non-treated cells except for the same CDNOD2 subject that could
not be correctly classiﬁed using the whole gene set (Fig. 6a).
Because we identiﬁed a large variance across CDNOD2 patients on
gene expression level following MDP stimulation, we hypothe-
sized that a similar variation existed on miR-155 regulation level.
In order to test this, we focused on miR-155 and the seven target
genes identiﬁed above, and compared their MDP response
between individual CDNOD2 patients and pooled CDWT patients
(Supplementary Fig. 6), similarly to our previous gene expression
comparison in Fig. 4f,g. As expected, the CDNOD2 subject that
showed the smallest inﬂammatory responses at gene level also
displayed the most drastic loss of miR-155 upregulation and
downregulation of its seven validated targets (Supplementary Fig.
6). This variance across patients was conﬁrmed by qPCR analysis in
Fig. 3 Functional annotation of differentially expressed genes between subject groups. a Enriched signiﬁcant GO terms (Bonferroni-corrected
P-values ≤ 0.05) for differential expressed genes between subject groups before MDP treatment. X-axis shows –log2(Bonferroni-corrected
P-values) and Y-axis shows GO terms. b As in a, but showing signiﬁcant GO terms for differential expressed genes between subject groups
after MDP treatment. c qPCR validation for a selected chemokine, CXCL1, which exhibits a large difference between the subject groups after
MDP treatment. X-axis shows subject groups before (dark green) and after MDP treatment (yellow). Numbers on top of the plot indicate the
number of biological replicates passing the qPCR thresholds. Each subject is visualized as black dots. Y-axis shows the relative gene expression
in log2 scale. Asterisks indicate level of signiﬁcance (two-sided t-test): * indicates P≤ 0.05, **P≤ 0.01, and ***P≤ 0.001. A single comparison with
a P-value close to the signiﬁcance threshold is indicated. d qPCR validation for a selected chemokine, CCL2, following the conventions of c
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the larger cohort. This showed that the loss of miR-155 induction
following MDP treatment varied across subjects, and the
corresponding level of downregulation of the miR-155 target
genes generally followed the miR-155 levels (Fig. 6b). In general,
CDNOD2 subjects displaying a reduced MDP response of gene level
also showed this on miR-155 level (Figs. 4h, 6b).
DISCUSSION
In this study we explored gene and miRNA expression in an initial
set of human blood monocytes using genome-wide high-
throughput sequencing techniques and veriﬁed our major
conclusions by applying qPCR analyses in a larger validation
cohort or THP-1 cells. All the samples were split by MDP treatment
and were broken up by subject groups, including patients with
NOD2 genotypes.
The results from pairwise differential expression studies
between the subjects demonstrated that the MDP treatment
resulted in considerable changes in gene expression. In particular,
CDWT patients showed a much stronger and wider inﬂammation
response compared to healthy controls. This is in line with a report
investigating the regulation of speciﬁc inﬂammatory pathways
upon innate engagement of monocytes in CD,36 but we here
show that these changes are more general, involving activating
NOD2 genotype and changes in innate signaling in Crohn’s disease
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cytokine receptors and their downstream signaling pathways. In
addition, it is noteworthy that while the major inﬂammatory
responses in the gene layer of CDWT patients corresponded to
upregulation, miRNA expression was generally downregulated in
these patients. This suggests that the innate hyper-responses
upon inﬂammation in CDWT patients might be also mediated by
generally reduced activity of the miRNA regulatory layer. Such a
NOD2-dependent phenotype of a pre-inﬂammatory innate hyper-
responsiveness state could be essential in shaping the inﬂamma-
tory processes found in CD. In line with this, there is evidence
of an increased risk of onset of CD in patients after infections
with intestinal pathogens, e.g., Salmonella spp. or Campylobacter
spp.37, 38
In contrast to mRNA levels, miRNA expression signatures
showed large differences between subject groups, but only two
miRNAs changed signiﬁcantly with MDP treatment including a key
inﬂammatory regulator, miR-155. Studies investigating NOD2-
speciﬁc miR-155 inductions have shown MDP stimuli alone has
limited impact on miR-155 expression in human dendritic cells,15
mouse macrophages,27 and embryonic ﬁbroblasts.39 Our results
demonstrated that MDP could induce miR-155 and its host gene
in human monocytes expressing WT NOD2, and this induction was
particularly strong in monocytes from CD patients, suggesting the
NOD2-based induction on miR-155 might differ across both cell
and disease types.
Previous studies have shown that the NOD2 loss-of-function
SNPs lead to decreased immune response,40, 41 but the differences
between individual subjects and type of mutations were not
addressed. Here, we showed that the effect of NOD2 loss-of-
function SNPs is diverse: some individuals from our CDNOD2 cohort
lost the MDP response, while some could mount an inﬂammatory
response similar to that of WT NOD2 subjects. This observation
was reﬂected on both general gene expression proﬁles, on miR-
155 levels and on its target genes. Patients carrying the SNP13
HOM appeared to have the largest response loss, although to
investigate the detailed effect of respective genotype, expression
quantitative trait loci analyses across a much larger population will
be necessary.
As we have not induced or rescued NOD2 mutations, these
results are based on correlations between genotype and
phenotype. However, as reduced induction of miR-155 in the
CDNOD2 group occurred only when treating with MDP (a NOD2
agonist) and not when treating with LPS or intact bacteria, it is
highly likely that the NOD2 mutations are the main drivers for the
phenotypes observed and by extension, that inﬂammatory
pathways not involving NOD2 are likely intact in these patients.
Additional mutations carried by these patients may modulate the
MDP response and may explain the wide MDP-response repertoire
in CDNOD2 patients. Such mutations may not only affect protein-
coding genes but also regulatory sites, including the disruption of
miRNA-binding sites, which have been reported to occur in
immune-associated genes, including NOD2 and IRGM.42, 43 How-
ever, to analyze such cases, genome-wide genotyping is
necessary.
In summary, our study identiﬁed substantial and novel changes
in NOD2 signaling of CDNOD2 and CDWT patients. The ﬁrst group
had on average dampened MDP responses, but the global
response was highly varied across individuals, on both gene and
miR-155 regulation levels. The CDWT group was characterized by a
pre-inﬂammatory innate hyper-responsive phenotype and thus
responds much stronger to MDP than cells from healthy controls.
This hyper-responsive phenotype was characterized by activation
a wide range of cytokine receptors and potentially also by a
general downregulation of miRNA expression in these patients.
Both types of dysregulated innate responses could, in different
ways, increase susceptibility to intestinal inﬂammation in response
to commensal bacteria. Moreover, we have shed light on an
underappreciated role of miRNAs in identifying disease-speciﬁc
and genotype-speciﬁc alterations in CD.
METHODS
Study population and genotyping
The patient population in this study was derived from a total of 57 healthy
controls (i.e., without any known GI disorders) and 236 patients with well-
established CD attending the IBD Clinic at Department of Gastroenterol-
ogy, Medical Section, Herlev Hospital. The diagnostic criteria for CD were
based on established guidelines44 applying clinical, radiologic, endoscopic,
and histologic criteria. Screening for the common NOD2 polymorphisms
(i.e., SNP8 [Arg702Trp], SNP12 [Gly908Arg], and SNP13 [Leu1007fsinsC])
was performed as previously described.45 All participants in this study were
WT in respect to autophagy-related 16-like 1 (ATG16L1) genotype. Patients
included in the sequencing and validation studies were in complete
clinical remission for at least 4 weeks prior to inclusion (Harvey-Bradshaw
index ≤5),46 and did not receive glucocorticoids or biologics for at least 3
Fig. 4 MDP-dependent miRNA and gene expression response within subject groups. a Left: Heat map as in Fig. 2a showing the two miRNAs
that were differential expressed as a response to MDP within a subject group (schematic on top shows the analyzed comparisons). Right: qPCR
validations for miR-155 are following the conventions of Fig. 3c. Asterisks indicate level of signiﬁcance (two-sided paired t-test): * indicates P≤
0.05, **P≤ 0.01, and ***P≤ 0.001. b qPCR analysis of miRNA-155 expression LPS or intact E. coli in monocytes from CD patients, broken up by
NOD2 genotype and treatment. Y-axis shows the log2 normalized fold change of mir-155 vs. expression control (see Supplementary Methods
for normalization): dots strand for individual patients. Asterisks indicate level of signiﬁcance (two-sided paired t-test): * indicates P≤ 0.05, **P≤
0.01, and ***P≤ 0.001. c Left: As in left of a, but showing genes that were differential expressed as a response to MDP within a subject group.
The black arrow highlights the outlier CDNOD2 subject that shows no substantial change in response to MDP. Right: qPCR validations of IRAK2
and MAPK3 genes are shown in the right panel, organized as in the right of panel a. d Venn diagrams showing the overlap of upregulated
genes in response to MDP within subject groups. e Venn diagrams showing the overlap of downregulated genes in response to MDP within
subject groups. f Degree of inﬂammatory gene response of individual CDNOD2 patients compared to the average response of CDWT patients
from the exploratory cohort. The inﬂammatory response is measured in a set of 1095 genes that were upregulated in CDWT. X-axis shows log2
fold change of the 1095 genes in CDWT patients after MDP. Y-axis shows corresponding fold changes in individual CDNOD2 patients. Each dot
corresponds to one gene, colored by individual CDNOD2 patients. Solid lines represent ﬁtted linear models for each CDNOD2 patient using the
loess approach; 95% conﬁdence intervals are indicated as gray shadows. The dashed diagonal in black corresponds to equivalent inﬂammatory
response between CDNOD2 and CDWT patients. Genes located above the diagonal will correspond to stronger inﬂammatory response in a
CDNOD2 patient than the average CDWT response. Conversely, genes located below the diagonal will correspond to decreased inﬂammatory
response in CDNOD2 vs. CDWT patients. Genes with high log2 fold changes (>4) are considered high MDP responders (see main text). g As in e,
but for the 565 downregulated genes in CDWT patients following MDP stimulation. The two parts of the plot indicating stronger or weaker
inﬂammatory response in a CDNOD2 are now swapped to the opposite. Genes with low log2 fold changes (<−4) are considered high MDP
responders (see main text). h Relative loss of inﬂammatory response in individual CDNOD2 patients compared to average CDWT patients in the
validation cohort by qPCR. Each pair of horizontal bar plots shows the average degree of inﬂammatory response loss for a CDNOD2 patient,
expressed as the average difference vs. CDWT patients for three upregulated genes in CDWT patients (CXCL1, CCL2, and IRAK2, left panel) and
four downregulated genes in CDWT patients (MAPK3, PALD1, MAVS, and FLI1, right panel). Error bars indicate the standard error of the mean
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preceding months. Long-term treatment with thiopurines was, however,
allowed if the dosing had been stable for more than 2 months. For RNA-
Seq and small RNA-Seq, monocytes were isolated from peripheral blood
samples from three subject groups (N = 7 in total): (I) healthy controls with
WT NOD2 (N = 2), (II) CD patients with WT NOD2 (CDWT) (N = 2), and (III) CD
patients with NOD2 SNPs (CDNOD2; one SNP13 homozygote—replicate 1,
one SNP13 heterozygote and SNP12 heterozygote—replicate 2, and one
SNP13 heterozygote and SNP8 heterozygote—replicate 3) (N = 3). Subse-
quently, miRNA/mRNA patterns identiﬁed in the RNA-Seq exploratory
experiments were tested in a larger cohort (N = 29 in total) where
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monocytes were obtained from (I) healthy controls with WT NOD2 (N = 10),
(II) CDWT (N = 11), (III) CDNOD2 (mixed NOD2 polymorphisms) (N = 8). The
monocytes isolated from each participant were grown with or without
MDP stimulation (see Supplementary Methods) for sequencing and qPCR
analysis. Supplementary Table 1 shows additional subject data. Validations
of miRNA-gene interactions were done with eight biological replicates in
TPH-1 cells (see Supplementary Materials and Methods).
Real-time qPCR validation of mRNAs and miRNAs
RNA was puriﬁed from monocytes and THP-1 cells, and converted to cDNA
as described in Supplementary Methods. Primer sequences are shown in
Supplementary Table 2. For each primer pair, only the samples that passed
qPCR thresholds were used in respective analyses (see “Methods”).
Numbers of samples passing thresholds are shown on top of correspond-
ing ﬁgures. Two-sided t-tests qPCR values were used as default statistical
tests between two groups. Paired tests were conducted for comparisons
within subject groups shown in Fig. 4 and Supplementary Fig. 4. P≤ 0.05
was used as signiﬁcance cutoff. For miRNA transfection experiments in
THP-1 cells, validations were considered “strong” if miR-155-transfected
samples vs. no transfected samples and miR-155-transfected samples vs.
control-transfected samples were both signiﬁcant. Validations were
considered “weak” either if P < 0.06 in both comparisons, or if P≤ 0.05 in
one of the two comparisons. Validations were considered “negative” if
none of the above applied.
RNA-Seq and small RNA-Seq preparation, mapping and
quantiﬁcation
Total RNA and short RNAs were puriﬁed using the Nucleospin RNA II
isolation kit (Macherey-Nagel) as recommended by the manufacturer.
Quantity and purity were determined on a NanoDrop1000, all samples had
a 260/280 nm absorbance >1.9. Illumina libraries were constructed using
TruSeq Stranded mRNA Sample Prep Kit and TruSeq Small RNA Library
Preparation Kit (Illumina) following the manufacturer’s protocols. The
libraries were sequenced on an Illumina Genome Analyser IIx running
sequencing 76 cycles, single read, for the mRNA libraries, and 36 cycles,
single read, for the short RNA libraries. Adapters were trimmed from reads,
which were then, ﬁltered by quality and mapped to the hg19 assembly
(see Supplementary Methods).
Differential expression analysis
Since our samples were derived from three subject groups and two MDP
conditions, many types of pair-wise comparisons between groups were
feasible, which would answer different types of questions (Fig. 1). Three
group comparisons were performed as shown in Fig. 1: (1) between patient
groups “before MDP treatment” (green arrows), (2) between subject
groups “after MDP treatment” (yellow arrows), and (3) between expression
proﬁles of the same subject group before and after treatment “MDP
response” (red arrows).
Fig. 5 Identiﬁcation of miR-155-gene associations. a miRNA-gene association network showing miR-155-gene interactions identiﬁed. Line
color summarizes the qPCR-based transfection analysis results in the exploratory cohort (shown in b–h). Strong validations (bold lines,
corresponding to b–e) and weak validations (gray lines, corresponding to f–h), and interactions that failed validations are shown as dotted
lines. Strong and weak criteria are described in “Methods” (b–h). qPCR results of miR-155 transfected THP1 cells. Y-axis shows relative qPCR
expression of the gene indicated on top of the plot. X-axis shows boxplots for cells that were not transfected, miR-155-transfected cells, and
control-transfected cells. Dots indicate individual samples. Asterisks indicate level of signiﬁcance (two-sided t-test): * indicates P≤ 0.05, **P≤
0.01, and ***P≤ 0.001. P-values for tests that are borderline signiﬁcant are shown (see Methods). b–e show strong validation cases, f–h shows
weak validation cases. i Summary of evidence for miR-155 regulation of the selected genes, from mirTarBase and this study. Black boxes
indicate the evidence from the indicated type of experiments from mirTarBase. “Strong” and “weak” categories refer to the classiﬁcation of
validations in b–h
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panel) and two selected miR-155 target genes (PALD and FLI1, right panel). The plot follows the same conventions as Fig. 4h
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For differential expression of genes in the above pair-wise comparisons,
we conducted a combined analysis using DESeq47 and Cuffdiff,48 where we
required an adjusted P-value≤ 0.05 (Benjamini–Hochberg False Discovery
Rate, FDR) from DESeq combined with a non-adjusted P-value≤ 0.05
from Cuffdiff (shown in main ﬁgures). The reciprocal analysis requiring
FDR≤ 0.05 from Cuffdiff combined with a non-adjusted P-value≤ 0.05
from DESeq did not give substantially different results (shown in
Supplementary Figs. 1, 3–5). Differential expression analysis for miRNAs
was performed by DESeq47 requiring a FDR≤ 0.05. All differentially
expressed genes analyzed with both methods and miRNAs are listed in
Supplementary Table 3.
Code availability
Aside from the programs mentioned above, computational analyses were
performed in R. Code is available by request.
Ethical approval
The study was approved by the Scientiﬁc Ethics Committee of the
Copenhagen Capital Region. Written informed consents from all included
subjects were obtained prior to participation, and the project fulﬁlled the
Helsinki V Declaration.
ACKNOWLEDGEMENTS
This work was supported by grants from Axel Muusfeldts Foundation, Holger og Ruth
Hesses Mindefond, Else og Mogens Wedell-Wedellsborgs Foundation, Direktør Kurt
Bønnelycke og hustru fru Grethe Bønnelyckes Foundation, P. A. Messerchmidt og
Hustrus Foundation, the Foundation of Aase and Ejnar Danielsen, the Danish Council
for Independent Research, the Lundbeck Foundation, and the Novo Nordisk
Foundation. We thank Hanne Fuglsang, Nine Scherling, Noor Irmam, and Tine
Helene Soendergaard for excellent technical assistance. We thank Kim Jensen for
access to PCR instruments.
DATA SHARING
Small RNA and RNA-Seq data are deposited in the GEO database, ID: GSE69446.
AUTHOR CONTRIBUTIONS
Y.C. and M.S. are shared ﬁrst authors. M.B. and J.B. are shared second authors. A.S., J.B.
S., and O.H.N. designed the study and supervised the project. Y.C. analyzed the data.
Y.C. and A.S. made the ﬁgures. M.S. made the sequencing libraries. M.S., M.B., J.B., Y.L.,
and M.C. made qPCR and miRNA validations. J.B.S. and O.H.N. did patient allocation.
Y.C., M.S., J.B.S., O.H.N., and A.S. wrote the manuscript.
COMPETING INTERESTS
The authors declare that they have no competing interests.
REFERENCES
1. Baumgart, D. C. & Sandborn, W. J. Crohn’s disease. Lancet 380, 1590–1605
(2012).
2. Danese, S. & Fiocchi, C. Ulcerative colitis. N. Engl. J. Med. 365, 1713–1725 (2011).
3. Abraham, C. & Cho, J. H. Inﬂammatory bowel disease. N. Engl. J. Med. 361,
2066–2078 (2009).
4. Kalla, R., Ventham, N. T., Satsangi, J. & Arnott, I. D. R. Crohn’s disease. Br. Med. J.
349, g6670–g6670 (2014).
5. Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture
of inﬂammatory bowel disease. Nature 491, 119–124 (2012).
6. McGovern, D. P. B., Kugathasan, S. & Cho, J. H. Genetics of inﬂammatory bowel
diseases. Gastroenterology 149, 1163–1176.e2 (2015).
7. Braat, H., Peppelenbosch, M. P. & Hommes, D. W. Immunology of Crohn’s disease.
Ann. N. Y. Acad. Sci. 1072, 135–154 (2006).
8. Hugot, J. P. et al. Association of NOD2 leucine-rich repeat variants with sus-
ceptibility to Crohn’s disease. Nature 411, 599–603 (2001).
9. Ogura, Y. et al. A frameshift mutation in NOD2 associated with susceptibility to
Crohn’s disease. Nature 411, 603–606 (2001).
10. Mo, J. et al. Pathogen sensing by nucleotide-binding oligomerization domain-
containing protein 2 (NOD2) is mediated by direct binding to muramyl dipeptide
and ATP. J. Biol. Chem. 287, 23057–23067 (2012).
11. Salem, M., Seidelin, J. B., Rogler, G. & Nielsen, O. H. Muramyl dipeptide responsive
pathways in Crohn’s disease: from NOD2 and beyond. Cell. Mol. Life Sci. 70,
3391–3404 (2013).
12. Watanabe, T. et al. Muramyl dipeptide activation of nucleotide-binding oligo-
merization domain 2 protects mice from experimental colitis. J. Clin. Invest. 118,
545–559 (2008).
13. Seidelin, J. B., Broom, O. J., Olsen, J. & Nielsen, O. H. Evidence for impaired
CARD15 signalling in Crohn’s disease without disease linked variants. PLoS ONE 4,
e7794 (2009).
14. Chen, Y. et al. miR-122 targets NOD2 to decrease intestinal epithelial cell injury in
Crohn’s disease. Biochem. Biophys. Res. Commun. 438, 133–139 (2013).
15. Brain, O. et al. The intracellular sensor NOD2 induces microRNA-29 expression in
human dendritic cells to limit IL-23 release. Immunity 39, 521–536 (2013).
16. Chuang, A. Y., Chuang, J. C., Zhai, Z., Wu, F. & Kwon, J. H. NOD2 expression is
regulated by microRNAs in colonic epithelial HCT116 cells. Inﬂamm. Bowel. Dis.
20, 126–135 (2014).
17. Kalla, R. et al. microRNAs: new players in IBD. Gut 64, 504–517 (2015).
18. Sayed, D. & Abdellatif, M. microRNAs in development and disease. Physiol. Rev.
91, 827–887 (2011).
19. Bai, J. et al. Integrating analysis reveals microRNA-mediated pathway crosstalk
among Crohn’s disease, ulcerative colitis and colorectal cancer. Mol. Biosyst. 10,
2317–2328 (2014).
20. O’Connell, R. M., Taganov, K. D., Boldin, M. P., Cheng, G. & Baltimore, D. microRNA-
155 is induced during the macrophage inﬂammatory response. Proc. Natl. Acad.
Sci. U.S.A. 104, 1604–1609 (2007).
21. Jablonski, K. A., Gaudet, A. D., Amici, S. A., Popovich, P. G. & Guerau-de-Arellano,
M. Control of the inﬂammatory macrophage transcriptional signature by miR-155.
PLoS ONE 11, e0159724 (2016).
22. Seddiki, N., Brezar, V., Rufﬁn, N., Lévy, Y. & Swaminathan, S. Role of miR-155 in the
regulation of lymphocyte immune function and disease. Immunology 142, 32–38
(2014).
23. Van der Goten, J. et al. Integrated miRNA and mRNA expression proﬁling in
inﬂamed colon of patients with ulcerative colitis. PLoS ONE 9, e116117–e116117
(2013).
24. Fasseu, M. et al. Identiﬁcation of restricted subsets of mature microRNA abnor-
mally expressed in inactive colonic mucosa of patients with inﬂammatory bowel
disease. PLoS ONE 5, e13160 (2010).
25. Singh, U. P. et al. miR-155 deﬁciency protects mice from experimental
colitis by reducing T helper type 1/type 17 responses. Immunology 143, 478–489
(2014).
26. Wang, P. et al. Inducible microRNA-155 feedback promotes type I IFN signaling in
antiviral innate immunity by targeting suppressor of cytokine signaling 1. J.
Immunol. 185, 6226–6233 (2010).
27. Koch, M., Mollenkopf, H.-J., Klemm, U. & Meyer, T. F. Induction of microRNA-155 is
TLR- and type IV secretion system-dependent in macrophages and inhibits DNA-
damage induced apoptosis. Proc. Natl. Acad. Sci. U. S. A. 109, E1153–E1162 (2012).
28. Tili, E. et al. Modulation of miR-155 and miR-125b levels following lipopoly-
saccharide/TNF-alpha stimulation and their possible roles in regulating the
response to endotoxin shock. J. Immunol. 179, 5082–5089 (2007).
29. Economou, M., Trikalinos, T. A., Loizou, K. T., Tsianos, E. V. & Ioannidis, J. P. A.
Differential effects of NOD2 variants on Crohn’s disease risk and phenotype in
diverse populations: a metaanalysis. Am. J. Gastroenterol. 99, 2393–2404 (2004).
30. Strober, W., Asano, N., Fuss, I., Kitani, A. & Watanabe, T. Cellular and molecular
mechanisms underlying NOD2 risk-associated polymorphisms in Crohn’s disease.
Immunol. Rev. 260, 249–260 (2014).
31. Pathak, S. et al. miR-155 modulates the inﬂammatory phenotype of intestinal
myoﬁbroblasts by targeting SOCS1 in ulcerative colitis. Exp. Mol. Med. 47, e164
(2015).
32. Xu, G. et al. Transcriptome and targetome analysis in MIR155 expressing cells
using RNA-seq. RNA 16, 1610–1622 (2010).
33. O’Connell, R. M., Rao, D. S. & Baltimore, D. microRNA regulation of inﬂammatory
responses. Annu. Rev. Immunol. 30, 295–312 (2012).
34. Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a
reference resource for gene and protein annotation. Nucleic Acids Res. 44,
D457–D462 (2016).
35. Hsu, S.-D. et al. miRTarBase update 2014: an information resource for experi-
mentally validated miRNA-target interactions. Nucleic Acids Res. 42, D78–D85
(2013).
36. Santaolalla, R., Fukata, M. & Abreu, M. T. Innate immunity in the small intestine.
Curr. Opin. Gastroenterol. 27, 125–131 (2011).
NOD2 genotype and changes in innate signaling in Crohn’s disease
Y Chen et al
10
npj Genomic Medicine (2017)  3 Published in partnership with the Center of Excellence in Genomic Medicine Research
37. Gradel, K. O. et al. Increased short- and long-term risk of inﬂammatory bowel
disease after salmonella or campylobacter gastroenteritis. Gastroenterology 137,
495–501 (2009).
38. García Rodríguez, L. A., Ruigómez, A. & Panés, J. Acute gastroenteritis is followed
by an increased risk of inﬂammatory bowel disease. Gastroenterology 130, 1588–1594
(2006).
39. Schulte, L. N., Westermann, A. J. & Vogel, J. Differential activation and functional
specialization of miR-146 and miR-155 in innate immune sensing. Nucleic Acids
Res. 41, 542–553 (2013).
40. Li, J. et al. Regulation of IL-8 and IL-1beta expression in Crohn’s disease associated
NOD2/CARD15 mutations. Hum. Mol. Genet. 13, 1715–1725 (2004).
41. Moreira, L. O. et al. The TLR2-MyD88-NOD2-RIPK2 signalling axis regulates a
balanced pro-inﬂammatory and IL-10-mediated anti-inﬂammatory cytokine
response to gram-positive cell walls. Cell. Microbiol. 10, 2067–2077 (2008).
42. Landi, D. et al. Polymorphisms within micro-RNA-binding sites and risk of
sporadic colorectal cancer. Carcinogenesis 29, 579–584 (2008).
43. Brest, P. et al. A synonymous variant in IRGM alters a binding site for miR-196 and
causes deregulation of IRGM-dependent xenophagy in Crohn’s disease. Nat.
Genet. 43, 242–245 (2011).
44. Van Assche, G. et al. The second European evidence-based consensus on the
diagnosis and management of Crohn’s disease: deﬁnitions and diagnosis. J.
Crohns Colitis 4, 7–27 (2010).
45. Yazdanyar, S. & Nordestgaard, B. G. NOD2/CARD15 genotype and common
gastrointestinal diseases in 43,600 individuals. J. Intern. Med. 267, 228–236
(2010).
46. Harvey, R. F. & Bradshaw, J. M. A simple index of Crohn’s-disease activity. Lancet 1,
514 (1980).
47. Anders, S. & Huber, W. Differential expression analysis for sequence count data.
Genome Biol. 11, R106 (2010).
48. Trapnell, C. et al. Differential gene and transcript expression analysis of RNA-seq
experiments with TopHat and Cufﬂinks. Nat. Protoc. 7, 562–578, doi:10.1038/
nprot.2012.016 (2012).
This work is licensed under a Creative Commons Attribution 4.0
International License. The images or other third party material in this
article are included in the article’s Creative Commons license, unless indicated
otherwise in the credit line; if the material is not included under the Creative Commons
license, users will need to obtain permission from the license holder to reproduce the
material. To view a copy of this license, visit http://creativecommons.org/licenses/by/
4.0/
© The Author(s) 2017
Supplementary Information accompanies the paper on the npj Genomic Medicine website (doi:10.1038/s41525-016-0001-4).
NOD2 genotype and changes in innate signaling in Crohn’s disease
Y Chen et al
11
Published in partnership with the Center of Excellence in Genomic Medicine Research npj Genomic Medicine (2017)  3 
